NASDAQ:SEER

Seer Competitors

$53.86
-3.06 (-5.38 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$53.36
Now: $53.86
$57.50
50-Day Range
$38.67
MA: $49.46
$56.92
52-Week Range
$38.37
Now: $53.86
$86.55
Volume343,450 shs
Average Volume511,150 shs
Market Capitalization$3.28 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Seer (NASDAQ:SEER) Vs. ABCL, SANA, ABCM, NUVB, IBRX, and IMCR

Should you be buying SEER stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Seer, including AbCellera Biologics (ABCL), Sana Biotechnology (SANA), Abcam (ABCM), Nuvation Bio (NUVB), ImmunityBio (IBRX), and Immunocore (IMCR).

AbCellera Biologics (NASDAQ:ABCL) and Seer (NASDAQ:SEER) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.

Profitability

This table compares AbCellera Biologics and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbCellera BiologicsN/AN/AN/A
SeerN/AN/AN/A

Valuation and Earnings

This table compares AbCellera Biologics and Seer's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbCellera BiologicsN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for AbCellera Biologics and Seer, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbCellera Biologics00503.00
Seer02202.50

AbCellera Biologics presently has a consensus target price of $52.80, indicating a potential upside of 86.90%. Seer has a consensus target price of $68.00, indicating a potential upside of 26.25%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, equities research analysts clearly believe AbCellera Biologics is more favorable than Seer.

Summary

AbCellera Biologics beats Seer on 3 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Sana Biotechnology (NASDAQ:SANA) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Seer and Sana Biotechnology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Sana Biotechnology02202.50

Seer presently has a consensus price target of $68.00, indicating a potential upside of 26.25%. Sana Biotechnology has a consensus price target of $40.00, indicating a potential upside of 59.74%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Seer.

Profitability

This table compares Seer and Sana Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Sana BiotechnologyN/AN/AN/A

Valuation & Earnings

This table compares Seer and Sana Biotechnology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Sana BiotechnologyN/AN/AN/AN/AN/A

Summary

Sana Biotechnology beats Seer on 1 of the 1 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Abcam (NASDAQ:ABCM) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Earnings and Valuation

This table compares Seer and Abcam's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
AbcamN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for Seer and Abcam, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Abcam04302.43

Seer currently has a consensus target price of $68.00, suggesting a potential upside of 26.25%. Abcam has a consensus target price of $22.00, suggesting a potential upside of 12.47%. Given Seer's stronger consensus rating and higher possible upside, research analysts plainly believe Seer is more favorable than Abcam.

Profitability

This table compares Seer and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
AbcamN/AN/AN/A

Summary

Seer beats Abcam on 2 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Nuvation Bio (NYSE:NUVB) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Profitability

This table compares Seer and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Nuvation BioN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Seer and Nuvation Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Nuvation Bio00603.00

Seer currently has a consensus target price of $68.00, indicating a potential upside of 26.25%. Nuvation Bio has a consensus target price of $17.40, indicating a potential upside of 74.52%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Seer.

Earnings and Valuation

This table compares Seer and Nuvation Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Summary

Nuvation Bio beats Seer on 3 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Valuation and Earnings

This table compares Seer and ImmunityBio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Seer and ImmunityBio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
ImmunityBio00103.00

Seer currently has a consensus price target of $68.00, indicating a potential upside of 26.25%. ImmunityBio has a consensus price target of $25.00, indicating a potential upside of 38.35%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Seer.

Profitability

This table compares Seer and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
ImmunityBioN/AN/AN/A

Summary

ImmunityBio beats Seer on 2 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Profitability

This table compares Seer and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
ImmunocoreN/AN/AN/A

Valuation and Earnings

This table compares Seer and Immunocore's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Seer and Immunocore, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Immunocore01202.67

Seer currently has a consensus target price of $68.00, indicating a potential upside of 26.25%. Immunocore has a consensus target price of $54.3333, indicating a potential upside of 37.55%. Given Immunocore's stronger consensus rating and higher possible upside, analysts clearly believe Immunocore is more favorable than Seer.

Summary

Immunocore beats Seer on 2 of the 2 factors compared between the two stocks.


Seer Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AbCellera Biologics logo
ABCL
AbCellera Biologics
1.5$28.25-0.0%$7.61 billionN/A0.00Increase in Short Interest
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$25.04-3.4%$4.70 billionN/A0.00News Coverage
Abcam logo
ABCM
Abcam
1.5$19.56-0.6%$4.43 billionN/A0.00Lockup Expiration
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$9.97-0.4%$2.17 billionN/A0.00Analyst Report
Insider Buying
IBRX
ImmunityBio
1.7$18.07-7.2%$1.98 billionN/A0.00Gap Down
Immunocore logo
IMCR
Immunocore
1.3$39.50-16.5%$1.70 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.7$46.04-0.1%$1.55 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$35.47-9.0%$1.54 billionN/A0.00
EWTX
Cricut
0.3$28.15-1.0%$1.34 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.29-11.0%$1.34 billionN/A0.00Analyst Report
KNTE
Kinnate Biopharma
1.7$30.72-7.6%$1.34 billionN/A0.00Increase in Short Interest
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.99-11.4%$1.33 billionN/A0.00Earnings Announcement
Analyst Report
Insider Selling
Increase in Short Interest
News Coverage
Vor Biopharma logo
VOR
Vor Biopharma
1.9$33.72-13.6%$1.25 billionN/A0.00
FDMT
4D Molecular Therapeutics
1.1$37.68-5.1%$1.01 billionN/A0.00Increase in Short Interest
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$17.45-2.9%$974.01 millionN/A0.00Analyst Report
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$29.59-2.5%$942.15 millionN/A0.00Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.96-8.3%$870.42 millionN/A0.00Analyst Report
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.94-7.1%$848.39 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$23.99-4.0%$842.03 millionN/A0.00Analyst Report
Increase in Short Interest
PHAR
Pharming Group
0.0$13.00-1.9%$829.48 millionN/A0.00Decrease in Short Interest
News Coverage
FNCH
Finch Therapeutics Group
2.0$16.66-2.0%$785.44 millionN/A0.00Analyst Report
News Coverage
SGTX
Sigilon Therapeutics
1.4$19.88-6.2%$626.08 millionN/A0.00Increase in Short Interest
News Coverage
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$21.65-17.8%$543.96 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$23.89-12.3%$543.69 millionN/A0.00Gap Down
Inventiva logo
IVA
Inventiva
1.4$13.60-2.9%$525.37 millionN/A0.00Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.54-2.0%$496.21 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Landos Biopharma logo
LABP
Landos Biopharma
1.8$11.26-5.8%$451.73 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.75-2.8%$451.17 millionN/A0.00
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.13-5.6%$446.09 millionN/A0.00Gap Up
PRTG
Portage Biotech
0.0$28.17-3.8%$340.38 millionN/A0.00Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.61-2.5%$306.86 millionN/A-2.98
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.87-3.6%$291.75 millionN/A-2.72
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.83-3.9%$269.69 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$10.94-7.3%$209.16 millionN/A0.00Increase in Short Interest
LBPH
Longboard Pharmaceuticals
1.9$12.15-2.4%$205.54 millionN/A0.00Analyst Report
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$22.90-5.4%$159.09 millionN/A0.00
GANX
Gain Therapeutics
1.7$14.02-5.8%$158.90 millionN/A0.00Analyst Report
VINC
Vincerx Pharma
1.0$19.05-0.6%$156.31 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$7.33-11.2%$140.73 millionN/A0.00News Coverage
LGVN
Longeveron
0.3$7.49-2.3%$140.12 millionN/A0.00
UPC
Universe Pharmaceuticals
0.0$3.92-4.3%$85.26 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$14.46-6.3%$56.51 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.31-2.3%$53.37 millionN/A0.00Gap Down
VIRI
Virios Therapeutics
1.3$5.90-0.8%$49.15 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.29-2.1%$38.75 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.87-5.1%$33.17 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3N/AN/A$23.39 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$35.01-12.4%$16.25 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.84-4.9%$15.69 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.20-12.8%$2.47 millionN/A0.00Gap Up
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.